An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate ...

Shares of UroGen Pharma (NASDAQ:URGN) lost ~47% on Wednesday after an FDA advisory committee voted against the company’s ...

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...